Miran Kenk

Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Tables 1-2

Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Material. Study protocol

ca, de (code pays fourni par la source)

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Neil Eric Fleshner, Rui Miguel Marques Bernardino, Jonathan I. Izawa, Darrel Drachenberg et autres

PURPOSE Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation …

ca, au (code pays fourni par la source)

The Metformin Active Surveillance Trial for Low-Risk Prostate Cancer

Neil Eric Fleshner, Rui Miguel Marques Bernardino, Jonathan I. Izawa, Darrel Drachenberg et autres

ca, nz, hk, au (code pays fourni par la source)

Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Material. Study protocol

Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Tables 1-2

Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Material. Study protocol

Data from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Abstract Purpose: Early treatment intensification with neoadjuvant therapy may improve outcomes in high-risk, localized prostate cancer (PCa) patients treated with radical prostatectomy (RP). Our objective was to compare pathologic, oncologic, and safety outcomes of neoadjuvant abiraterone acetate plus leuprolide acetate with or …

Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Tables 1-2

Biospecimen Qualification in a Clinical Biobank of Urological Diseases

Olga A. Kofanova, Sangita Paul, Achilleas Pexaras, Camille Bellora et autres

Development of novel biomarkers for diagnosis of disease and assessment of treatment efficacy utilizes a wide range of biospecimens for discovery research. The fitness of biospecimens for the purpose of biomarker development depends on the clinical characteristics of the donor and on …

lu, ca (code pays fourni par la source)

Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Tables 1-2

Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin et autres

Supplementary Tables 1-2